United Laboratories International Holdings Ltd
HKEX:3933
Operating Margin
United Laboratories International Holdings Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| HK |
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
25.9B HKD |
25%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
775.3B USD |
38%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.9B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
48%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
223.9B CHF |
32%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
177.1B GBP |
23%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
197.4B CHF |
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
219.3B USD |
36%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
140B USD |
25%
|
United Laboratories International Holdings Ltd
Glance View
United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on United Laboratories International Holdings Ltd's most recent financial statements, the company has Operating Margin of 25.1%.
You don't have any saved screeners yet